Medical Patent Law Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Allon Therapeutics

Officials from Allon Therapeutics report latest developments

This trend article is an immediate alert from NewsRx to identify the most recent news developments at Allon Therapeutics.

Report 1: Allon Therapeutics, Inc., (NPC), The Neuro Protection Company, announced IRB (Institutional Review Board) approval to begin enrolling patients for a phase II human clinical trial evaluating the company's lead product AL-108.

The trial will evaluate the efficacy of AL-108 in improving cognitive function in patients who suffer from Mild Cognitive Impairment (MCI), often a pre-cursor to Alzheimer disease.

Gordon McCauley,...

• View Other Issues of Medical Patent Law Weekly
  
• View Other NewsRx Publications